Description: This research report examines the ban of the use of genetic testing information in life insurance mortality.

Description: Employers, health plans, stop-loss insurers and reinsurers are all affected by the high cost of treating cancer. In recent years, cutting-edge pharmaceuticals, bone marrow transplants and CAR-T cell therapies have driven very high cost trends for cancer, with more emerging therapies on the horizon. In this session, we will review these new treatments, showcase models that aid in understanding the range of likely financial effects of the current, expanded, and likely-to-be approved indications for cell therapies that will treat certain patients affected by lymphoma, leukemia, and multiple myeloma. This session will explain important considerations for modeling Medicare, Medicaid versus commercial populations, key risk concerns caused by the size of enrollee pools, and important differences between the various therapies that affect modeling. We will also discuss averted cost, health outcomes, pricing levels, and risks caused by provider billing practices.

Description: Table of contents

Description: This section presents book reviews and summarizes recent publications: 'Measurement of Mortality' by Gershenson, 'Decision and Influence Processes in Private Pension Plans' by McNulty, Jr., 'Economic Assumptions Underlying the Medium-Range Projections of the Federal OASDI Trust Funds' by Lukaczer, 'Eighth Actuarial Valuation of the Assets and Liabilities under the Railroad Retirement Act as of 12/31/1959' by Railroad Retirement Board, 'Life Insurance' 9th edition by Maclean, 'Evaluation of a Single Visit Cardiovascular Examination' by US National Health Survey, 'Guide to Health Insurance Underwriting' by Tilton and Yochem, 'Duration of Limitation of Activity Due to Chronic Conditions, US, July 1959 - June 1969' by US National Health Survey.

Description: This discussion is about the litigation risks pension actuaries face, and the standards of care actuaries should take to protect themselves from malpractice and errors & omissions 'E&O' claims. From the Record of the Society of Actuaries Vol. 18, No. 2.

Description: Eager to learn more about what an InsurTech is, how they operate in the insurance ecosystem and how actuaries can participate in this ecosystem? Join actuaries, InsurTechs and participants in the ecosystem to discuss the recent research report on InsurTechs by the SOA. At the conclusion of the session, attendees will be able to: • Know more about InsurTechs and how they operate • Understand how insurers work with InsurTechs • Discover how actuaries can participate in this ecosystem • Learn practical lessons from both InsurTechs and actuaries This session is presented by the Entrepreneurial & Innovation Section.

Description: This report has been written to provide a primer on the measurement known as R0 (pronounced “R-naught”), which is commonly used in epidemiology. The R0 metric has received extensive press coverage since the outbreak due to its importance in the measurement of the spread of COVID-19.

Description: A special issue of the Annals of Actuarial Science, focusing on insurance data science, was published on July 1. As explained by the editors—Katrien Antonio (KU Leuven), Christophe Dutang (Université Paris Dauphine), and Andreas Tsanakas (City, University of London)—the theme of this issue grew out of the rapid and transformative developments in the field, with the increased use of computational statistics, machine learning and artificial intelligence models in insurance applications. While the special issue has been associated with the Second Insurance Data Science Conference, held in June 2019 at ETH Zurich, the published papers come from a wider and very distinguished pool of authors.

Description: Web page for posting of several studies on the potential impact of pandemic influenza on the U.S. life insurance industry and the potential economic effects.